Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pressure-sensitive aqueous humor outflow pathway refers primarily to the conventional (trabecular) outflow route in the eye, which is responsible for maintaining intraocular pressure (IOP) by regulating the drainage of aqueous humor from the anterior chamber. This pathway, comprised of the trabecular meshwork (TM) including the juxtacanalicular connective tissue (JCT), Schlemm’s canal, and collector channels, is highly responsive to changes in IOP and adjusts resistance accordingly to maintain homeostasis. Impaired function or increased resistance within this pathway leads directly to elevated IOP—a major risk factor for primary open-angle glaucoma (POAG). Many current glaucoma therapies target either increasing trabecular outflow facility or reducing its resistance.
Increase trabecular outflow facility, Reduce outflow resistance
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pressure-Sensitive Aqueous Humor Outflow Pathway.